Ne
Non verificato

Neurogene Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieSaluteScienza
06/07/2026
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
01/07/2026
Scienza
Biotecnologia
Medicina - Varie
Sanità
Farmaceutica
Salute
Mercato azionario
Neurogene Inc. Announces Pricing of $125 Million Public Offering
1.00
30/06/2026
Mercato azionario
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Neurogene Inc. Announces Proposed Public Offering
1.00
29/06/2026
Eventi
Web e Social Network
Biotecnologia
Salute
Medicina - Varie
Neurogene Reports Positive Long-term Clinical Data from Phase 1/2 Trial of NGN-401 Gene Therapy for Rett Syndrome
1.00
08/06/2026
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Industria
Neurogene Announces Successful Completion of Dosing in Embolden™ Registrational Trial of NGN-401 for Rett Syndrome
1.00
02/06/2026
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
12/05/2026
Mercato azionario
Eventi
Salute
Biotecnologia
Medicina - Varie
Farmaceutica
Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates
1.00
12/05/2026
Eventi
Industria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Neurogene Highlights Data at ASGCT Meeting Supporting Therapeutic Rationale for ICV Delivery Method in CNS-targeted Gene Therapy
1.00
06/05/2026
Mercato azionario
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
1.00
28/04/2026
Eventi
Scienza
Biotecnologia
Farmaceutica
Salute
Medicina - Varie
Neurogene Announces Upcoming Presentation on the Therapeutic Rationale for ICV Delivery in CNS-Targeted Gene Therapy
1.00

Recapiti

Social Media

Seguaci
0
Compatibilità
0